New chemo cocktail aims to outsmart aggressive myeloma
NCT ID NCT00869232
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tests a combination of eight chemotherapy drugs given in lower doses and shorter cycles to people with high-risk multiple myeloma. The goal is to prevent myeloma cells from regrowing between treatments, leading to longer remissions and better survival. The study enrolls 90 newly diagnosed patients with high-risk features.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
a combination of chemotherapy drugs: Velcade, melphalan, thalidomide, dexamethasone, cisplatin, doxorubicin, cyclophosphamide, and etoposide
What this could lead to
If it works, this approach could lead to longer remissions and better survival for people with high-risk multiple myeloma.
What could go wrong
This is a phase II trial with only 90 participants, so results may not apply to everyone. The intensive chemo regimen also carries risks like infection and organ damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72205, United States